XML 39 R25.htm IDEA: XBRL DOCUMENT v3.6.0.2
17. Subsequent Event (Notes)
12 Months Ended
Dec. 31, 2016
Subsequent Events [Abstract]  
Subsequent Events [Text Block] 17. SUBSEQUENT EVENT

On February 15, 2017, we acquired all the issued and outstanding stock of RainDance Technologies, Inc. (RainDance) for approximately $87 million including certain assumed net liabilities. Cash payments at closing were $82.9 million. The acquisition will be included in our Life Science segment’s results of operations from the acquisition date and will be accounted for as a business combination. The amount of acquisition-related costs was minimal as Bio-Rad primarily represented itself during the acquisition process. The goodwill to be recorded will not be deductible for income tax purposes.
We are presently unable to report the purchase price allocation or the evaluation of the transaction, as more time is needed to complete the information transfer from the seller and include all information into a valuation of individual assets and liabilities.

RainDance's foundational intellectual property portfolio and product lines encompass a wide range of biological reactions in droplets, with potential applications in life science research and clinical research. These genomic tools provide ultra-sensitive detection of genetic variations in cancer as well as inherited and infectious diseases, enabling research in areas such as non-invasive liquid biopsy. We believe that RainDance's droplet-based solutions will extend our reach into next-generation sequencing applications and strengthen our position in the area of Droplet Digital™ PCR, offering customers with solutions for a wide range of nucleic acid detection applications.